AUAUniversity Podcast Series: Episode No.291

Non-Muscle Invasive Bladder Cancer: Expert Guidance for Urologists

CME Available: https://auau.auanet.org/node/41961

After participating in this CME activity, participants will be able to:

1. Assess the risk stratification of low, intermediate, and high risk NMIBC patients to appropriately guide treatment decisions.
2. Employ diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities.
3. Tailor treatment strategies based on individual patient characteristics and tumor biology to highlight the potential of personalized medicine in improving the management of NMIBC.
4. Identify new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies.
5. Properly manage adverse events associated with NMIBC treatment.

Acknowledgements
Support provided by an independent educational grant from:
ImmunityBio, Inc.
Merck & Co., Inc.
UroGen Pharma, Inc.